2 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Involved-site Radiation Therapy: new trials by email Literature Review of Involved-site Radiation Therapy trials Research Report on Involved-site Radiation Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin - Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1875 | 2023-05-11 | 2026-10-22 |
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma pembrolizumab, gemcitabine, vinorelbine - Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 257 | 2018-08-01 | 2026-09-24 |
Hodgkin Disease (1) · Recurrence (1)
Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (2) · Canada (1) · Puerto Rico (1)
Alison Moskowitz, MD (1) · Kara M Kelly (1)
U10CA180886 (1)